Abstract
Chagas disease represents a serious burden for millions of people worldwide. Transmitted by the protozoan parasite Trypanosoma cruzi, this neglected tropical disease causes more than 10,000 deaths each year and is the main cause of heart failure in Latin America, where it is endemic. Although most cases are concentrated in Latin American countries, Chagas disease has been increasingly reported in non-endemic regions, where the low level of public awareness on the subject contributes to the growing prevalence of the disease. The available medicines are characterized by several safety and efficacy drawbacks that prevent millions of people, particularly those with advanced disease, from receiving adequate treatment. This urgent need has stimulated the emergence of diverse initiatives dedicated to the research and development (R&D) of novel therapeutic agents for Chagas disease. Public-private partnerships have been responsible for a significant increase in the investments in R&D programs and major advancements have been achieved over the past ten years. A number of collaborative projects have been leveraged by this organizational model, which privileges sharing of data, expertise, and resources between research institutions and pharmaceutical companies. Among the current strategies employed by these consortia, target-based and phenotypic screenings have achieved the most promising results. This article provides an overview on the current status and recent advances in Chagas disease drug discovery.
Keywords: American trypanosomiasis, Cruzain, CYP51, Trypanosoma cruzi, Neglected tropical diseases, Inhibitors.
Current Topics in Medicinal Chemistry
Title:Advances and Progress in Chagas Disease Drug Discovery
Volume: 16 Issue: 20
Author(s): Leonardo G. Ferreira, Marcelo T. de Oliveira and Adriano D. Andricopulo
Affiliation:
Keywords: American trypanosomiasis, Cruzain, CYP51, Trypanosoma cruzi, Neglected tropical diseases, Inhibitors.
Abstract: Chagas disease represents a serious burden for millions of people worldwide. Transmitted by the protozoan parasite Trypanosoma cruzi, this neglected tropical disease causes more than 10,000 deaths each year and is the main cause of heart failure in Latin America, where it is endemic. Although most cases are concentrated in Latin American countries, Chagas disease has been increasingly reported in non-endemic regions, where the low level of public awareness on the subject contributes to the growing prevalence of the disease. The available medicines are characterized by several safety and efficacy drawbacks that prevent millions of people, particularly those with advanced disease, from receiving adequate treatment. This urgent need has stimulated the emergence of diverse initiatives dedicated to the research and development (R&D) of novel therapeutic agents for Chagas disease. Public-private partnerships have been responsible for a significant increase in the investments in R&D programs and major advancements have been achieved over the past ten years. A number of collaborative projects have been leveraged by this organizational model, which privileges sharing of data, expertise, and resources between research institutions and pharmaceutical companies. Among the current strategies employed by these consortia, target-based and phenotypic screenings have achieved the most promising results. This article provides an overview on the current status and recent advances in Chagas disease drug discovery.
Export Options
About this article
Cite this article as:
G. Ferreira Leonardo, T. de Oliveira Marcelo and D. Andricopulo Adriano, Advances and Progress in Chagas Disease Drug Discovery, Current Topics in Medicinal Chemistry 2016; 16 (20) . https://dx.doi.org/10.2174/1568026616666160413124902
DOI https://dx.doi.org/10.2174/1568026616666160413124902 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Recent Progress in Graphene Derivatives/Metal Oxides Binary Nanocomposites Based Chemi-resistive Sensors for Disease Diagnosis by Breath Analysis
Current Analytical Chemistry Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Hypertension: Basics Concepts and the Evolving Role of Novel Treatments
Current Hypertension Reviews Cardiovascular Effects of Liraglutide
Current Hypertension Reviews DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
Current Cardiology Reviews Psoriatic Arthritis – Review of the Immunologic, Clinic and Therapeutic Aspects of an Inflammatory Systemic Disease
Current Rheumatology Reviews Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Current Medicinal Chemistry MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics New Investigational Drugs for the Management of Acute Heart Failure Syndromes
Current Medicinal Chemistry Daily Melatonin Administration Attenuates Age-Dependent Disturbances of Cardiovascular Rhythms
Current Aging Science Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets